SBC Medical Group Holdings Incorporated

Second-quarter 2026 revenue was $49 million, up 13% year over year. Adjusted EBITDA was $20 million, up 32% year over year, and adjusted EBITDA margin was 41%. The company said clinic revenue year to date rose 11%, same-clinic revenue increased 6%, average spend per visit in the quarter rose 9%, locations reached 287, up 34 year over year, and trailing-12-month customer visits were 6.92 million, up 10%. Management also said enhanced call center functions and stronger support for Gorilla and Rize clinics are expected to add roughly $15 million per year on a full-year basis, with about half of that unrealized in Q3 and Q4 and full contribution starting next fiscal year.

CEO Yoshiyuki Aikawa said the company had completed the structural reforms it started in 2025 and that SBC's growth is reaccelerating. He emphasized that the company responded to intense competition in Japan’s aesthetic market by renewing marketing, fees, and treatments, and he said SBC expects its AI deployment to become a competitive advantage and improve both convenience and profitability. He also framed the long-term vision around becoming a leading longevity platform, expanding beyond aesthetics into orthopedics, ophthalmology, fertility, dentistry, and other healthcare categories.

CFO Yuya Yoshida focused on the operating leverage in the quarter and said profitability improved faster than revenue. He said the SG&A increase was only slight and was driven in part by a one-time secondary offering cost, not by a broader expense trend. On the fee increases, he said the timing varies by item, some impact was already slightly included in June, about half will show up in Q3 and Q4, and most of the gains should flow through to profit because the services are tied to fixed costs. He also noted the company’s plan to use AI to keep headcount roughly flat while scaling to 1,000 clinics by 2035, and said SBC has ample cash to support organic investment and M&A.

Analysts focused on why domestic aesthetic performance has improved, and management pointed to a full review of marketing, website content, fees, and media spend, plus the appointment of a new Chief Marketing Officer. On competition, management said the peak of new-clinic competition may have passed and that SBC’s scale, brand strength, equipment purchasing power, and AI capabilities put it in a stronger position than single-brand peers. Questions on OrangeTwist centered on what SBC learned and what happens next; management said the new leadership has accelerated reforms and that SBC is considering expanding the U.S. business, potentially raising its stake and using both OrangeTwist roll-ups and SBC-branded locations. On Southeast Asia and longevity, management highlighted traction in Vietnam, Singapore, Thailand, and inbound demand, and said a longevity center and online platform are planned for next year.